Lynne Georgopoulos, VP Regulatory Strategy, Certara describes the company's platform to optimize pediatric drug development using biosimulation. With an eye on pediatric diseases, Certara is employing modeling and simulation to determine how a drug developed for adults may be metabolized in children, including neonates. They are also operationalizing clinical trials to be more efficient and potentially less invasive which is important when working with young children.

@certara #biosimulation #RACEforChildren #rarediseases #pediatriconcology

Certara.com

Download the transcript here